TG治疗 TGTX 深 沪
等待开盘 05-12 09:30:00 美东时间
42.80
-0.125
-0.29%
华盛通- 最 高44.65
- 今 开42.75
- 成交量 206.92万股
- 最 低 36.25
- 昨 收 42.925
- 总市值 616.32万
- 52周最高 44.65
- 市盈率 静 --
- 换手率 1436.92%
- 52周最低 25.28
- 委 比 -90.00%
- 总股本 0.00亿
- 历史最高 56.74
- 量 比 0.88
- 振 幅 19.57%
- 历史最低 0.9563
- 每 手 1
- 风险率 3.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多TG Therapeutics Board Authorizes Increase To Share Repurchase Program From $100M To $300M
TG Therapeutics, Inc. ("TG" or "the Company"), (NASDAQ:TGTX), today announced that it has entered into a new five-year, $750 million senior secured credit facility with funds managed by Blue Owl Capital ("Blue Owl"). As
03-19 19:38
Precision BioSciences Lands $7.5M Milestone Payment From TG Therapeutics In MS Drug Trial
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today
03-02 20:12
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
TG Therapeutics Publishes Five-Year Study On BRIUMVI MS Treatment
At Year 5, 97.7% of continuous-treatment participants and 95.0% of switch participants remained relapse-free.
02-17 20:37
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.
2025-11-03 22:14
Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
2025-11-03 19:11
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
TG Therapeutics' CEO, Michael S. Weiss, will participate in the Jefferies Global Healthcare Conference in New York City on June 4, 2025, with a fireside chat at 12:50 PM ET. A live webcast will be available on the company’s website. TG Therapeutics is focused on developing treatments for B-cell diseases, including BRIUMVI, approved for treating multiple sclerosis. Contact details for investors and media are provided.
2025-06-02 12:00
Evaluating TG Therapeutics: Insights From 4 Financial Analysts
During the last three months, 4 analysts shared their evaluations of TG Therape...
2024-09-19 05:01
HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $49 Price Target
HC Wainwright & Co. analyst Edward White reiterates TG Therapeutics (NASDAQ:TGTX) with a Buy and maintains $49 price target.
2024-09-19 01:02
